Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]